Gene-based therapeutic angiogenesis

Seminars in Thoracic and Cardiovascular Surgery

Volumn 15, Issue 3, 2003, Pages 236-249

  Yeh, Jennifer L ^a   Giordano, Frank J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Coronary artery disease; Gene therapy; Peripheral vascular disease

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENIC FACTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR 5; GLYCERYL TRINITRATE; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LENTIVIRUS VECTOR; MATRIX PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACENTAL GROWTH FACTOR; PLASMID DNA; PLASMID VECTOR; RECOMBINANT VASCULOTROPIN; SCATTER FACTOR; TETRACYCLINE; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN C; ZINC FINGER PROTEIN;

ADENO ASSOCIATED VIRUS; ANGIOGENESIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EXPOSURE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SCREENING; FEVER; GENE DELIVERY SYSTEM; GENE THERAPY; HEART EDEMA; HUMAN; LEG EDEMA; LIVER DYSFUNCTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLASMA HALF LIFE; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME; VASCULAR DISEASE; VIRAL GENE DELIVERY SYSTEM;

EID: 0141743422     PISSN: 10430679     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-0679(03)70003-3     Document Type: Article

References (61)

1. Simons M, Bonow RO, Chronos NA, et al: Clinical trials in coronary angiogenesis: Issues, problems, consensus: An expert panel summary. Circulation 102:E73-E86, 2000
2. Henry TD, Annex BH, McKendall GR, et al: The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 107:1359-1365, 2003
3. Simons M, Annex BH, Laham RJ, et al: Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 105:788-793, 2002
4. Banai S, Jaklitsch MT, Shou M, et al: Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89:2183-2189, 1994
5. Baffour R, Berman J, Garb JL, et al: Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: Dose-response effect of basic fibroblast growth factor. J Vasc Surg 16:181-191, 1992
6. Takeshita S, Zheng LP, Brogi E, et al: Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 93:662-670, 1994
7. Harada K, Friedman M, Lopez JJ, et al: Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol 270:H1791-H1802, 1996
8. Sellke FW, Li J, Stamler A, et al: Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia. Surgery 120:182-188, 1996
9. Henry TD, Rocha-Singh K, Isner JM, et al: Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J 142:872-880, 2001
10. Hendel RC, Henry TD, Rocha-Singh K, et al: Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: Evidence for a dose-dependent effect. Circulation 101:118-121, 2000
11. Bale TL, Giordano FJ, Hickey RP, et al: Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proc Natl Acad Sci U S A 99:7734-7739, 2002
12. Shizukuda Y, Tang S, Yokota R, et al: Vascular endothelial growth factor-induced endothelial cell migration and proliferation depend on a nitric oxide-mediated decrease in protein kinase Cdelta activity. Circ Res 85:247-256, 1999
13. Babaei S, Teichert-Kuliszewska K, Zhang Q, et al: Angiogenic actions of angiopoietin-1 require endothelium-derived nitric oxide. Am J Pathol 162:1927-1936, 2003
14. Ziche M, Morbidelli L: Nitric oxide and angiogenesis. J Neurooncol 50:139-148, 2000
15. Lee PC, Salyapongse AN, Bragdon GA, et al., Impaired wound healing and angiogenesis in eNOS-deficient mice. Am J Physiol 277:H1600-H1608, 1999
16. Asahara T, Masuda H, Takahashi T, et al: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221-228, 1999
17. Asahara T, Murohara T, Sullivan A, et al: Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967, 1997
18. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, Asahara T: Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nature Medicine 4:434-438, 1999
19. Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389-395, 2000
20. Conway EM, Collen D, Carmeliet P: Molecular mechanisms of blood vessel growth. Cardiovasc Res 49:507-521, 2001
21. Schaper W, Buschmann I: Arteriogenesis, the good and bad of it. Eur Heart J 20:1297-1299, 1999
22. Buschmann I, Schaper W: The pathophysiology of the collateral circulation (arteriogenesis). J Pathol 190:338-342, 2000
23. Schaper W: Therapeutic arteriogenesis has arrived. Circulation 104:1994-1995, 2001
24. Ferrara N, Carver-Moore K, Chen H, et al: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442, 1996
25. Ferrara N: Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 280:C1358-C1366, 2001
26. Isner JM, Pieczek A, Schainfeld R, et al: Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348:370-374, 1996
27. Baumgartner I, Pieczek A, Manor O, et al: Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97:1114-1123, 1998
28. Rosengart TK, Lee LY, Patel SR, et al: Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg 230:466-470, 1999
29. Rosengart TK, Lee LY, Patel SR, et al: Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100:468-474, 1999
30. Asahara T, Takahashi T, Masuda H, et al: VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18: 3964-3972, 1999
31. Post MJ, Laham R, Sellke FW, et al: Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc Res 49:522-531, 2001
32. Grines CL, Watkins MW, Helmer G, et al: Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105:1291-1297, 2002
33. Giordano FJ, Ping P, McKirnan MD, et al: Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 2:534-539, 1996
34. Sengupta S, Gherardi E, Sellers LA, et al: Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 23:69-75, 2003
35. Rosen EM, Grant DS, Kleinman HK, et al: Scatter factor (hepatocyte growth factor) is a potent angiogenesis factor in vivo. Symp Soc Exp Biol 47:227-234, 1993
36. Weidner KM, Hartmann G, Sachs M, et al: Properties and functions of scatter factor/hepatocyte growth factor and its receptor c-Met. Am J Respir Cell Mol Biol 8:229-237, 1993
37. Giordano FJ, Johnson RS: Angiogenesis: The role of the microenvironment in flipping the switch. Curr Opin Genet Dev 11:35-40, 2001
38. Semenza GL: HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 13:167-171, 2001
39. Li J, Post M, Volk R, et al: PR39, a peptide regulator of angiogenesis. Nat Med 6:49-55, 2000
40. Hou D, Maclaughlin F, Thiesse M, et al: Widespread regional myocardial transfection by plasmid encoding Del-1 following retrograde coronary venous delivery. Catheter Cardiovasc Interv 58:207-211, 2003
41. Lee RJ, Springer ML, Blanco-Bose WE, et al: VEGF gene delivery to myocardium: Deleterious effects of unregulated expression. Circulation 102:898-901, 2000
42. Buckley RH: Gene therapy for SCID - a complication after remarkable progress. Lancet 360:1185-1186, 2002
43. Riessen R, Rahimizadeh H, Blessing E, et al: Arterial gene transfer using pure DNA applied directly to a hydrogel-coated angioplasty balloon. Hum Gene Ther 4:749-758, 1993
44. Cappelletti M, Zampaglione I, Rizzuto G, et al: Gene electro-transfer improves transduction by modifying the fate of intramuscular DNA. J Gene Med 5:324-332, 2003
45. Ikeda Y, Gu Y, Iwanaga Y, et al: Restoration of deficient membrane proteins in the cardiomyopathic hamster by in vivo cardiac gene transfer. Circulation 105:502-508, 2002
46. Vale PR, Losordo DW, Milliken CE, et al: Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 103:2138-2143, 2001
47. Giordano FJ: Retrograde coronary infusion: A superior route to deliver therapeutics to the heart? J Am Coll Cardiol (in press)
48. Banai S, Jaklitsch MT, Casscells W, et al: Effects of acidic fibroblast growth factor on normal and ischemic myocardium. Circ Res 69:76-85, 1991
49. Majesky MW: A little VEGF goes a long way. Therapeutic angiogenesis by direct injection of vascular endothelial growth factor-encoding plasmid DNA. Circulation 94: 3062-3064, 1996
50. Unger EF, Banai S, Shou M, et al: Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol 266:H1588-H1595, 1994
51. Mack CA, Patel SR, Schwarz EA, et al: Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 115:168-176, 1998
52. Makinen K, Manninen H, Hedman M, et al: Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: A randomized, placebo-controlled, double-blinded phase II study. Mol Ther 6:127-133, 2002
53. GenVec, American Heart Association Scientific Sessions, November 2002
54. Losordo DW, Vale PR, Symes JF, et al: Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98:2800-2804, 1998
55. Symes JF, Losordo DW, Vale PR, et al: Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 68:830-836, 1999
56. Losordo DW, Vale PR, Hendel RC, et al: Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 105:2012-2018, 2002
57. Isner JM, Vale PR, Symes JF, et al: Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ Res 89:389-400, 2001
58. Asahara T, Bauters C, Zheng LP, et al: Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 92: II365-II371, 1995 (suppl 9)
59. Lubiatowski P, Gurunluoglu R, Goldman CK, et al: Gene therapy by adenovirus-mediated vascular endothelial growth factor and angiopoietin-1 promotes perfusion of muscle flaps. Plast Reconstr Surg 110:149-159, 2002
60. Thurston G, Suri C, Smith K, et al: Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286:2511-2514, 1999
61. Rebar EJ, Huang Y, Hickey R, et al: Induction of angiogenesis in a mouse model using engineered transcription factors. Nat Med 8:1427-1432, 2002